Osiris poised to lead stem cell drug market

12/27/2007 | Sun (Baltimore), The

Osiris Therapeutics may conquer the stem cell drug market in 2008, with clinical trials of its candidates showing promise. Three pivotal late-stage trials are under way to test intravenous drug Prochymal for Crohn's disease and graft-versus-host disease. The company also plans to conduct a Phase III trial for Chondrogen, which yielded positive results in midstage tests in treating knee pain caused by osteoarthritis.

View Full Article in:

Sun (Baltimore), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA